Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis

Abstract Small-cell lung cancer (SCLC) is a recalcitrant cancer characterized by high metastasis. However, the exact cell type contributing to metastasis remains elusive. Using a Rb1L/L/Trp53L/L mouse model, we identify the NCAMhiCD44lo/– subpopulation as the SCLC metastasizing cell (SMC), which is progressively transitioned from the non-metastasizing NCAMloCD44hi cell (non-SMC). Integrative chromatin accessibility and gene expression profiling studies reveal the important role of the SWI/SNF complex, and knockout of its central component, Brg1, significantly inhibits such phenotypic transition and metastasis. Mechanistically, TAZ is silenced by the SWI/SNF complex during SCLC malignant progression, and its knockdown promotes SMC transition and metastasis. Importantly, ectopic TAZ expression reversely drives SMC-to-non-SMC transition and alleviates metastasis. Single-cell RNA-sequencing analyses identify SMC as the dominant subpopulation in human SCLC metastasis, and immunostaining data show a positive correlation between TAZ and patient prognosis. These data uncover high SCLC plasticity and identify TAZ as the key molecular switch in orchestrating SCLC phenotypic transition and metastasis.

(Continued on next page)

INTRODUCTION
Small-cell lung cancer (SCLC) is characterized by very poor prognosis, with ∼15% global lung cancer incidence and a five-year survival lower than 7% [1]. This can be largely attributed to the highly metastatic capability of SCLC. Most SCLC patients are initially diagnosed at extensive stage, characterized by nearby lung and/or distant metastases. Therefore, exploration of the mechanisms involved in SCLC metastasis is urgently needed so as to provide helpful insights into clinical management.
Previous studies have shown that ∼90% of human SCLC harbors concurrent inactivating mutations or deletions of Rb1 and Trp53 [2]. Homozygous deletion of these two alleles in mouse lung epithelia promotes SCLC development and dra-matic metastasis, which closely recapitulates human SCLC in the clinic [3]. Mouse SCLC in the Rb1 L/L /Trp53 L/L (RP) model typically expresses neuroendocrine markers including neuronal cell adhesion molecule (NCAM) and achaetescute complex homolog 1 (ASCL1), and frequently metastasizes into distant organs [3]. Concurrent deletion of P130, an Rb-related gene, or Pten in the RP model, significantly accelerates malignant progression and SCLC metastasis [4,5]. Moreover, upregulated Nuclear Factor I B (NFIB) expression is found to promote SCLC metastasis through increasing the accessibility of global chromatin [6][7][8].
SCLCs are characterized by high heterogeneity [9][10][11][12][13][14][15]. It is proposed that human SCLC is composed of four different subtypes based on SCLC, e.g. the CD24 hi CD44 lo EpCAM hi subpopulation from the RP model is identified as harboring a strong capability to form tumors in allograft assay [11]. Moreover, mouse SCLC is found to contain the neuroendocrine (NE) and non-neuroendocrine (non-NE) subpopulations according to distinct growth patterns in culture, with the NE subtype growing as suspension and the non-NE as adhesion [9]. The NE cells frequently express neuroendocrine markers including NCAM, synaptophysin (SYP) and ASCL1. In contrast, the non-NE cells tend to express mesenchymal markers such as VIMENTIN and CD44 [9]. It has been reported that the synergetic cooperation between NE and non-NE subpopulations is necessary for SCLC metastasis whereas neither subtype could metastasize on its own [9]. Therefore, the exact population responsible for SCLC metastasis still remains unknown.
The switch/sucrose-non-fermentable (mSWI/ SNF) complexes, including canonical BRG1/BRMassociated factor (BAF), polybromo-associated BAF (PBAF) and non-canonical BAF (ncBAF), are essential for chromatin remodeling [17,18]. All three complexes contain a core ATPase subunit, e.g. BRG1 (Brahma/SWI2-related gene 1, also called SMARCA4), which catalyzes the hydrolysis of ATP [18]. Previous studies reveal that the SWI/SNF complexes tend to function as tumor suppressors during cancer development. Consistently, a high incidence of BRG1 inactivating mutation is detected in multiple cancer types including lung cancer [19]. Previous studies show that BRG1 promotes cell cycle arrest and senescence through the retinoblastoma pathway in cancer cells [20,21]. Interestingly, recent studies have also indicated an oncogenic role of BRG1. For example, BRG1 promotes pancreatic intraepithelial neoplasia (PanIN) development and gastric cancer metastasis [22][23][24]. In SCLC, BRG1 is preferentially required for cancer progression when MAX (Myc-associated factor) is inactivated [25]. These findings indicate that BRG1 might function as tumor suppressor or oncogenic driver in a cell-type-or genetic-context-dependent manner.
It is well known that YAP/TAZ sustains self-renewal and tumor-initiating capability, and promotes cancer malignant progression and metastasis through epithelial-to-mesenchymal transition (EMT) [30]. The latest studies also reveal that YAP/TAZ might function as a tumor suppressor [32][33][34]. For instance, YAP expression is downregulated in breast cancer and knockdown of YAP promotes cancer cell migration and invasiveness [35]. Moreover, we have previously found that YAP acts as the barrier for adenocarcinoma-to-squamous-carcinoma transdifferentiation (AST) as well as for lung squamouscell carcinoma progression [33,36]. Nonetheless, the exact role of YAP/TAZ during SCLC metastasis has not been characterized yet.
We here identify NCAM hi CD44 lo/cells as the major subpopulation responsible for SCLC metastasis. Moreover, this subpopulation is progressively transitioned from the non-metastatic NCAM lo CD44 hi cells via the SWI/SNF-complexmediated TAZ silencing. Our data highlight the important link between epigenetically regulated TAZ and SCLC plasticity and metastasis.

Identification of the NCAM hi CD44 lo/subpopulation as SCLC metastasizing cells
To study SCLC heterogeneity during cancer malignant progression and metastasis, we first performed immunohistochemistry (IHC) staining in RP tumors using NE marker NCAM and mesenchymal marker CD44. In primary RP tumors, we indeed observed the heterogeneous expression pattern of these two markers intra-tumorally and inter-tumorally ( Fig. 1A and Table S1). We found that the percentage of NCAM hi CD44 lo/tumors, defined with over 50% of cancer cells highly expressing NCAM and with low or no CD44 expression [37], increased with malignant progression and metastasis (Fig. 1B, Fig. S1A and Table S1). Consistently, we found that distant organ metastases such as liver and kidney metastases uniformly exhibited the NCAM hi CD44 lo/expression pattern (Fig. 1A). These data indicate that the NCAM hi CD44 lo/subpopulation might be responsible for SCLC metastasis.
To test this, we then used Fluorescence Activated Cell Sorting (FACS) to isolate the NCAM hi CD44 lo/and NCAM lo CD44 hi subpopulations from primary RP tumors (Fig. 1C). Genotyping analyses confirmed the concurrent deletion of Rb1 and Trp53 in both subpopulations (Fig. S1B). We found that the NCAM hi CD44 lo/-   cells grew in culture as oncospheres with a suspension growth pattern (Fig. 1C), similar to classical human SCLC cell lines. In contrast, the NCAM lo CD44 hi cells grew as adhesion (Fig. 1C). Moreover, a higher ASCL1 level was detected in the NCAM hi CD44 lo/subpopulation (Fig. 1D). We then subcutaneously transplanted 5 × 10 6 cells from either the NCAM hi CD44 lo/or NCAM lo CD44 hi subpopulation into nude mice and waited for up to 10 weeks for distant organ metastasis analyses. Both subpopulations formed subcutaneous tumors at 100% in allograft assay, with comparable tumor growth ( Fig. S1C and D). In contrast, the metastasis analyses revealed a huge difference. Most mice (13 out of 15) from the NCAM hi CD44 lo/group had spontaneous metastases in the liver whereas only 1 out of 15 mice from the NCAM lo CD44 hi group displayed distant metastasis ( Fig. 1E and F). The liver metastases from the NCAM hi CD44 lo/group exhibited a characteristic marker expression pattern, similar to subcutaneous tumors ( Fig. 1G and H). These data demonstrate that the NCAM hi CD44 lo/cells are mainly responsible for SCLC metastasis. We hereafter refer to the NCAM hi CD44 lo/and NCAM lo CD44 hi subpopulations as SCLC metastasizing cell (SMC) and non-SCLC metastasizing cell (non-SMC), respectively.

Phenotypic transition from non-SMC to SMC contributes to SCLC metastasis
Consistent with SMC metastatic tumors, the liver metastasis lesion from the non-SMC allograft assay also exhibited the NCAM hi CD44 lo/expression pattern ( Fig. 2A and Fig. S2). We speculated that there might exist phenotypic transition from non-SMC to SMC during SCLC malignant progression. To test this, we established a non-SMC cell line stably expressing GFP, termed non-SMC-GFP, and performed a subcutaneous allograft assay (Fig. 2B). Immunofluorescence (IF) staining in allograft tumors revealed that ∼13 ± 2% GFP-positive cancer cells displayed the NCAM hi CD44 lo/pattern whereas the rest remained as a non-SMC expression pattern ( Fig. 2C and Table S2). Consistently, both suspension and adhesion growth patterns were observed when these allograft tumors were cultured in vitro (Fig. 2B). To further confirm such transition, we picked single-cell clones from non-SMC-GFP cells and performed allograft assay with the clonal non-SMC-GFP cell lines (Fig. 2D). Similarly, we found that these subcutaneous tumors also displayed the NCAM hi CD44 lo/pattern, ranging from 14 ± 2% to 20 ± 3% ( Fig. 2E and Table S2). A mixed growth pattern was also observed in culture (Fig. 2D). We further isolated the tran-sitioned SMC with NCAM hi CD44 lo/pattern and tested its metastasis capability using allograft assay. In contrast to no overt metastases in the non-SMC group, multiple distant organ metastases, e.g. lymph node, lung and liver metastases, were detectable in the transitioned SMC group ( Fig. 2F and G). We found that the liver metastases also displayed the NCAM hi CD44 lo/pattern (Fig. 2G). These data together convincingly proved the transition from non-SMC to SMC and highlighted the important role of such phenotypic transition in SCLC metastasis.

Brg1 knockout inhibits SMC phenotypic transition and SCLC metastasis
To further explore the molecular mechanisms underlying non-SMC-to-SMC transition, we performed RNA sequencing and comparatively analyzed the gene expression profiling of SMC and non-SMC. The small-cell neuroendocrine (SCN) signature has been recently established as an important index for SCLC metastasis [38]. Interestingly, we found a significant enrichment of SCN-signature-related pathways in SMC whereas non-SCN-related pathways (immune-related pathways) were enriched in non-SMC ( Fig. 3A and Tables S3 and S4). Real-time PCR data further confirmed the increased expression of SCN signature genes, including Ascl1, Insm1, Neurod1, Chga, Sox11 and Ttf1, in SMC (Fig. 3B). These data might partially explain the high metastasis capability of SMC. Epigenetic alterations have been implicated in cancer plasticity [39,40]. We performed the assay for transposase-accessible chromatin with nextgeneration sequencing (ATAC-seq) to determine the global chromatin accessibility of SMC and non-SMC. Our analyses on transcription start sites also revealed an overall reduced signal in the active promoter regions of SMC (Fig. 3C). The total reads of ATAC-seq for SMC and non-SMC were ∼36 million and 27 million, respectively. Chromatin remodelers, such as SWI/SNF complex, are critical for regulating chromatin architecture and accessibility [18]. We found that multiple members of the SWI/SNF complex, including the central catalytic ATPase Brg1, were markedly dysregulated between these two subpopulations (Fig. S3A). Real-time PCR quantification further confirmed the significant upregulation of Brg1 in SMC (Fig. 3D).
To test whether Brg1 is involved in the phenotypic transition and SCLC metastasis, we generated the Rb1 L/L /Trp53 L/L /Brg1 L/L (RPB) mouse cohort and performed comparative analyses of tumorigenesis, SCN signature enrichment and metastasis in parallel with the RP model (Fig. 3E). We found that Brg1 knockout significantly reduced the tumor  number (Fig. 3F, and Fig. S3B and C). Moreover, several SCN-signature-related genes, including Ascl1, Ttf1 and Sox11, were significantly downregulated in RPB tumors ( Fig. 3G and Fig. S3B). IHC staining of the NCAM and CD44 showed that the percentage of primary tumors with an SMC expression pattern was also decreased in the RPB group ( Fig. 3H and I and Table S5). Notably, no liver metastasis was detected in the RPB group in contrast to ∼50% incidence in the RP model ( Fig. 3J and K). These data support the conclusion that the SWI/SNF complex is important for SMC phenotypic transition and SCLC metastasis.

Epigenetic silencing of TAZ by SWI/SNF complex in SMC
To identify the downstream mediator of the SWI/SNF complex in contribution to SCLC phenotypic transition and metastasis, we first constructed the dysregulated transcriptional factor (TF) network through the integrative analyses of RNA-seq and ATAC-seq data as previously described [41]. We found that Ascl1 and Tead2 were top-ranked TFs with the highest number of dysregulated target genes in SMC and non-SMC respectively ( Fig. 4A    initializes neuronal reprogramming and is also included in the SCN biomarker genes [42]. TEAD family members are important TFs that function with cofactor YAP/TAZ in cancer malignant progression [30,43,44]. Gene set enrichment analysis revealed that the Hippo pathway was significantly enriched in non-SMC (Fig. 4C). Moreover, Taz/Yap stood out as top hits among the dysregulated components of the Hippo pathway (Fig. 4D). Using real-time PCR, we further confirmed the decreased expression of Taz/Yap in SMC vs. non-SMC cells (Fig. 4E and Fig. S3D).
We further asked whether Taz/Yap expression was regulated by Brg1. We found that Brg1 knockdown in SMC cells resulted in a significant upregulation of TAZ expression whereas the expression of YAP was downregulated (Fig. 4F and G and Fig. S3E). Such upregulation of TAZ was also detectable in RPB tumors in comparison to RP tumors ( Fig. 4H and J and Table S5). Moreover, we observed an obvious decreased chromatin accessibility at the promoter region of Taz in SMC (Fig. S3F), which might explain the reduced TAZ expression (Fig. 1D). A similar but lesser degree of chromatin accessibility change was also observed at the Yap promoter region in SMC (Fig. S3F). In support of this, TAZ level was obviously downregulated in primary tumors at extensive stage (Fig. S1A). Moreover, knockdown of Arid1a or Arid2, another two important components of the SWI/SNF complex, obviously upregulated TAZ expression in SMC cells ( Fig. S3G and H). However, YAP expression was only slightly upregulated with Arid2 knockdown, or even downregulated after Arid1a knockdown in SMC ( Fig. S3G and H). Moreover, we performed BRG1 Chromatin Immunoprecipitation real-time quantitative PCR (ChIP-qPCR) analysis and found that BRG1 could bind to the promoter region of Taz (Fig. S3I). These results together demonstrate that TAZ is silenced during non-SMC-to-SMC transition through SWI/SNF-complex-mediated epigenetic reprogramming.

TAZ knockdown promotes non-SMC-to-SMC transition and accelerates SCLC metastasis
To explore the function of TAZ in phenotype transition and SCLC metastasis, we performed Taz knockdown in non-SMC for allograft assay (Fig. 5A). We found that Taz knockdown in non-SMC upregulated NCAM and SCN-related genes, whereas it downregulated CD44, without a dramatic effect upon Yap expression ( Fig. 5B and Fig. S6A-C). Moreover, Taz knockdown also promoted the invasiveness in matrigel, colony formation in soft agar and anti-anoikis capability of non-SMC ( Fig. 5C and E). IF staining of allograft tumors showed that Taz knockdown promoted the appearance of the NCAM hi CD44 lo/pattern, resembling the SMC-derived tumors ( Fig. 5F and Fig. S6D). Importantly, knockdown of Taz in non-SMC promoted distant organ metastasis (Fig. 5G). IHC staining further confirmed that these metastases displayed the SMC expression pattern (Fig. 5H). These data together demonstrate that TAZ downregulation promotes phenotypic transition from non-SMC to SMC and SCLC metastasis.

Ectopic TAZ expression reversely promotes the transition from SMC to non-SMC and alleviates SCLC metastasis
To test if the phenotypic transition from non-SMC to SMC is reversible, we ectopically expressed a constitutive activated TAZ mutant (TAZ-4SA) [30] in SMC (Fig. 5I). We found that the downstream targets of TAZ, including Cyr61, Ctgf, Areg, Vim and Axl, were significantly upregulated after ectopic TAZ-4SA expression in SMC (Fig. S6E). Ectopic TAZ-4SA but not YAP-5SA [33] expression in SMC dramatically downregulated NCAM and upregulated CD44 expression in vitro, indicative of the potential reversible transition from SMC to non-SMC (Fig. 5J, Fig. S6F, and Tables S7 and S8). Moreover, the SCN score and related gene expression also decreased after ectopic TAZ-4SA ex-Natl Sci Rev, 2022, Vol. 9, nwab232  Taz  Ajuba  Ccnd1  Gli2  Yap  Tead2  Tcf7l2  Myc  Wnt4  Tcf7l1  Tgfb1  Sox2  Smad3  Snai2  Tcf7  Tead4  Wtip  Smad7  Tead3  Actb  Tead1 Stk3  pression ( Fig. 5K and L and Tables S7 and S8). Functional assays showed that TAZ-4SA expression markedly suppressed the matrigel invasiveness, colony formation in soft agar and anti-anoikis capability of SMC ( Fig. 5M and O). IF staining also showed that ectopic TAZ-4SA expression promoted the non-SMC expression pattern in comparison to SMC-derived subcutaneous tumors ( Fig. 5P and Fig. S6G). More importantly, ectopic TAZ-4SA expression significantly suppressed the liver metastases of SMC (Fig. 5Q). Furthermore, all the liver metastases consistently showed no TAZ expression (Fig. S6H). These findings support the conclusion that ectopic TAZ expression promotes reverse transition from SMC to non-SMC and alleviates SCLC metastasis.

Low TAZ level is associated with SCN signature enrichment and predicts poor prognosis of SCLC patients
To evaluate whether our findings are clinically relevant, we downloaded a public RNA-sequencing dataset of 112 human SCLCs [2,45] and analyzed the correlation between TAZ and SCN signature, and single-cell sequencing data of liver metastasis [15], to detect whether SMC exists in metastatic lesion, and collected 101 Chinese surgical specimens for prognosis analyses (Fig. 6A). Bioinformatic analyses showed that human SCLC with low TAZ expression (TAZ lo ) displays a significantly higher SCN score ( Fig. 6B and Table S9), indicative of strong metastasis capability. The SCN-signaturerelated pathways, including positive regulation of neurotransmitter transport, neurotransmitter secretion and synaptic vesicle membrane, were significantly enriched in TAZ lo SCLC (Fig. S7A). Consistently, most SCN-signature-related genes, including ASCL1, INSM1 and CHGA, were significantly increased in TAZ lo SCLC samples (Fig. 6C). Moreover, NCAM was increased, and CD44 was decreased in TAZ lo SCLC specimens (Fig. 6C), indicative of the SMC pattern of these samples. TEAD also decreased in these TAZ lo samples (Fig. 6C). Also, we observed a negative correlation between the SCNsignature-related genes and TAZ, and a positive cor-relation between CD44, TEAD2 and TAZ (Fig. S7B and Table S9). We further took advantage of the Ireland et al. single-cell RNA-sequencing data derived from SCLC liver metastasis [15]. Interestingly, we found that most SCLC metastatic cells showed high expression of NCAM with concurrent low expression of CD44, resembling the SMC pattern (Fig. 6D). Moreover, these cells showed high expression of the SCN signature markers INSM1 and NEUROD1, similar to the SMC in the RP model (Fig. 6D). Importantly, low or no TAZ expression was detected in these metastasis cells (Fig. 6D), confirming the silence of TAZ in metastasis.
Lastly, we put together a patient cohort containing 101 Chinese SCLC surgical specimens for immunostaining analyses of NCAM, CD44 and TAZ. Most of these patients were at limited stage without distant metastases. We found that high NCAM or low CD44 levels were significantly associated with worse patient overall survival (OS) (Fig. 6E and Table S10). Moreover, TAZ lo patients also showed a worse overall survival (Fig. 6F). These data together provide strong clinical evidence in support of our findings of SMC in the RP model.

DISCUSSION
SCLC is the most lethal form of lung cancer, characterized by highly metastatic capacity. A growing body of evidence based on mouse models has demonstrated that SCLC is highly heterogeneous with distinct subpopulations playing different roles during malignant progression and metastasis [5][6][7][8][9][10][11][12][13][14][15]. In this study, we identify the NCAM hi CD44 lo/cells in the RP model as the SCLC metastasizing cells. We further reveal that the SMCs are progressively transitioned from non-SMCs during SCLC malignant progression and metastasis. Our data further show that the SWI/SNF-complex-mediated epigenetic downregulation of TAZ is essential for driving such a phenotype transition. Moreover, TAZ activation is sufficient to drive the reverse transition from SMC to non-SMC and thus alleviate SCLC metastasis. With the support of clinical specimen analyses, our Natl Sci Rev, 2022, Vol. 9, nwab232  data demonstrate that the NCAM hi CD44 lo/cells are mainly responsible for SCLC metastasis and the SWI/SNF-TAZ axis importantly orchestrates SCLC plasticity and metastasis (Fig. 6G).
To assess SCLC heterogeneity in the RP model, we use both NE marker NCAM and mesenchymal marker CD44 to do the immunostaining and FACS analyses, and identify the NCAM hi CD44 lo/cells as the SCLC metastasizing cells. A previous study shows that mouse SCLC cells contain both NE and non-NE subpopulations [9]. However, neither subpopulation alone can metastasize and a synergetic cooperation is necessary for distant organ metastasis [9]. In contrast, our data show that the NCAM hi CD44 lo/cells harbor strong metastasis capability in allograft assay, and the tumors metastasize into multiple distant organs including the lymph node, lung and liver. Since the SMC defined here also expresses classical NE biomarkers, we reason that the NCAM hi CD44 lo/cells might belong to the NE subpopulation, but with higher metastasis potential. In other words, the NCAM hi CD44 lo/cells might represent the highly metastatic subpopulation of the NE subtype. In addition, we used primary NCAM hi CD44 lo/cells and demonstrated their robust metastatic capability, whereas Calbo et al. [9] employed tumor-derived cell lines for metastasis assays. Future efforts looking into the heterogeneity of the NE subtype will hopefully uncover more subpopulations linked to SCLC malignant progression and metastasis.
We also find that phenotypic transition from non-SMC to SMC contributes to SCLC metastasis, which closely links cancer plasticity and malignant progression. Indeed, recent data also show, during SCLC drug resistance acquisition, that Notch signaling promotes the transition from an NE to non-NE subtype and thus provides a niche for resisting drug treatment [10]. A similar transition from NE to non-NE subtypes has also been found in another recent study [15]. Metastasis and drug resistance are two major hurdles in clinical SCLC management. Understanding molecular mechanisms involved in the phenotypic transition in these two important events will hopefully provide a solid base for the development of a novel therapeutic strategy to treat SCLC in the clinic.
Through integrative analyses of gene expression profiling and chromatin accessibility, we find that SWI/SNF complexes play an important role during non-SMC-to-SMC transition. Although the SWI/SNF complex is generally considered to be tumor suppressive [46], our results indicate that this complex has a different role in SCLC progression. Knockout of its ATPase BRG1 inhibits such phenotypic transition and cancer metastasis, indicating the oncogenic function of the SWI/SNF complex as well as BRG1 in SCLC. In agreement with our observation, a previous study reported that BRG1 is important for the activation of NE transcriptional programs to upregulate MYC targets, and depletion of BRG1 strongly hinders cell growth, specifically in MAX-deficient SCLC tumors [25]. Consistently, we find that BRG1 knockdown suppresses neuronal gene expression and several SCN-signature-related genes in the SMC subpopulation. Likewise, the dual roles of ARID1A have also been revealed in cancer [47]. Thus, the exact function of the SWI/SNF complex and its subunit as tumor suppressor or oncogenic driver might be cell-type or genetic-context dependent and vary with the type of malignancy.
We further find that TAZ is an important downstream mediator of the SWI/SNF complex during SCLC phenotypic transition. Although both YAP and TAZ are significantly upregulated in non-SMC, only TAZ is significantly upregulated when Brg1 is knocked down in SMC. Similar findings are also observed when Arid1a or Arid2 is knocked down. Consistently, Brg1 knockout in an RP mouse upregulates TAZ and significantly inhibits SMC appearance and SCLC metastasis. Moreover, we find that low TAZ expression is associated with SCN signature enrichment. In agreement with these observations, previous studies have shown that high YAP/TAZ expression correlates with decreased NE markers [48], and YAP loss defines NE differentiation [49]. Meanwhile, NE lineage markers are dominant in the SCN signature, which is significantly Natl Sci Rev, 2022, Vol. 9, nwab232   (G) Working model illustrating the essential role of SWI/SNF-complex-mediated TAZ expression in controlling the phenotypic transition from non-SMC to SMC and SCLC metastasis. TAZ, which is epigenetically silenced by the SWI/SNF complex, functions as a critical molecular switch during the phenotypic transition from non-SMC to SMC and SCLC metastasis. Disruption of the SWI/SNF complex through BRG1 knockout promotes TAZ upregulation and thus inhibits the phenotypic transition and cancer metastasis. associated with SCLC malignant progression and metastasis [38,[50][51][52]. Of course, considering the redundant function and concurrent decrease of YAP and TAZ, it remains possible that YAP may also contribute to SCLC phenotypic transition and metastasis albeit independent of the SWI/SNF complex. Future efforts will be necessary to clarify the detailed regulatory mechanisms underlying YAP expression during SCLC phenotypic transition and metastasis.
Our findings from loss-of-function and gainof-function experiments support the tumorsuppressive role of TAZ in SCLC. YAP/TAZ is well established as oncogenic driver. Nonetheless, accumulated evidence has recently revealed the tumor-suppressive function of YAP/TAZ in multiple cancer types [53]. For instance, YAP restricts Wnt signals during intestinal regeneration, which results in rapid loss of intestinal crypts, and YAP loss promotes hyperplasia and microadenoma development [54]. In hematological cancer, low YAP level prevents nuclear ABL1-induced apoptosis and rescued YAP expression triggers cell death [55]. Another study shows that the growth inhibitory effect caused by LATS1/2 deletion is due to uncontrolled activation of YAP in colon cancer [56]. A recent report demonstrates that LATS1/2 promotes breast cancer cell growth through inhibition of YAP/TAZ [34]. Our findings with regard to the tumor-suppressive function of TAZ are also supported by clinical specimen analyses. Single-cell RNA-sequencing data support that the cancer cells from SCLC liver metastasis mainly display the SMC expression pattern and these metastatic cells show low or no expression of TAZ. Moreover, low TAZ level is significantly associated with poor patient survival. These data together support that TAZ works as a tumor suppressor in controlling SCLC plasticity and metastasis.

RP and RPB mouse cohort generation, maintenance and analyses
Mice were housed in a specific pathogen-free environment at the Shanghai Institute of Biochemistry and Cell Biology, and treated in accordance with protocols conforming to the ARRIVE guidelines and approved by the Institutional Animal Care and Use Committee of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (approval number: IBCB0011). Conditional knockout mice including Trp53 L/L , Rb1 L/L [3] and Brg1 L/L [57] alleles were generously provided by Drs. Tyler Jacks, Ronald A. DePinho and Pierre Chambon. Mice were crossed to obtain Rb1 L/L /Trp53 L/L (RP) and Rb1 L/L /Trp53 L/L /Brg1 L/L (RPB) cohorts. All experimental mice were maintained on a mixed genetic background as previously described [58]. Mice at 6-8 weeks old were treated with Adenovirus-CMV-Cre recombinase (Ad-Cre, 2 × 10 6 p.f.u.) by intratracheal intubation [59] to allow for Cre-lox mediated recombination of floxed alleles. Mouse tumors were used for immunostaining, FACS analyses, genomic DNA extraction and genotyping as previously described [3,57]. The primer sequences are shown in the supplementary data.

Statistical analysis
Statistical analyses were carried out using SPSS 16.0 or GraphPad Prism 5/7 software (San Diego, CA). The significance of differences was determined using a two-tailed Student's t test or chi-square test. Kaplan-Meier analysis with log-rank test was used to assess patients' survival between subgroups. P value <0.05 was considered to be statistically significant.

DATA AVAILABILITY
Sequence data have been deposited in Gene Expression Omnibus (GEO) with the primary accession codes GSE158091 (ATAC-seq of SMC and non-SMC), GSE158290 (RNA-seq of SMC and non-SMC) and GSE158293 (RNA-seq of SMC-Ctrl and SMC-TAZ-4SA).